Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 16, 2022 - Issue 8
Submit an article Journal homepage
57
Views
1
CrossRef citations to date
0
Altmetric
Special Report

A health condition index for assessing disease progression

Dimitris Petridisa Department of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, Thessaloniki, GreeceView further author information
,
Dimitris Matthaiosb Oncology Department, General Hospital of Rhodes, Rhodes, GreeceView further author information
,
Vaggelis Christakidisc Oncology Department, General Hospital of Serres, Serres, GreeceView further author information
,
Chrysanthi Sardelid Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, GreeceView further author information
,
Lutz Freitagd Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, GreeceView further author information
,
Haidong Huange Department of Respiratory & Critical Care Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, Changhai, ChinaView further author information
&
Paul Zarogoulidisf 3rd Department of Surgery, AHEPA University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece;g Pulmonary Oncology Department, Bioclinic Private Hospital, Thessaloniki, GreeceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5119-2207View further author information
ORCID Icon show all
Pages 867-873 | Received 01 Mar 2022, Accepted 26 Aug 2022, Published online: 07 Sep 2022

References

  • Perol M, Felip E, Dafni U, et al. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (nsq-NSCLC) with PD-L1-high expression using real-world data. Ann Oncol. 2022;33(5):511–521.
  • Frank MS, Bodtger U, Gehl J, et al. Actionable molecular alterations are revealed in majority of advanced non-small cell lung cancer patients by genomic tumor profiling at progression after first line treatment. Cancers (Basel). 2021;14(1):132.
  • Kerr KM, Bibeau F, Thunnissen E, et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer. 2021;154:161–175.
  • Shen -F-F, Guo W, Tian R-F, et al. Long-term survival with targeted therapy in an advanced non-small cell lung cancer patient based on genetic profiling. Transl Lung Cancer Res. 2020;9(2):373–378.
  • Vannitamby A, Hendry S, Irving L, et al. Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens. Lung Cancer. 2019;134:233–237.
  • Ng Kee Kwong F, Laggner U, McKinney O, et al. Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas. Histopathology. 2018;72(6):1024–1032.
  • Suda K, Rozeboom L, Rivard CJ, et al. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer. 2017;109:1–8.
  • Zhang H, Kong W, Zhao X, et al. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer. BMC Genomic Data. 2022;23(1):8.
  • Zhao Y, Wu J, Li L, et al. Guanylate-binding protein 1 as a potential predictor of immunotherapy: a pan-cancer analysis. Front Genet. 2022;13:820135.
  • Zarogoulidis P, Petridis D, Huang H, et al., Biopsy and re-biopsy for PD-L1 expression in NSCLC. association between PD-L1 and checkpoint inhibitor efficacy through treatment in NSCLC. A pilot study. Expert Rev Respir Med. 2021;15(11):1483–1491.
  • Zarogoulidis P, Christakidis V, Petridis D, et al., Connection between PD-L1 expression and standardized uptake value in NSCLC: an early prognostic treatment combination. Expert Rev Respir Med. 2021;15(5):675–679.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.